Noxopharm Announces Novel mRNA Vaccine Enhancer
Filed with ASX · · 4 pages · English
Preclinical first-in-class mRNA technologybased on company’s Sofra platform Smallest molecule of its type to have demonstrated strong activity against inflammation Developed in collaboration with strategic partner Hudson Institute of Medical Research Growing worldwide activity in multi-billion mRNA market Sydney, 28 March 2023:Innovative biotech companyNoxopharm Limited (ASX:NOX) announces the dev
Story so far
Earlier from Noxopharm
- Appendix 4D and Half Year 2023 Financial Report
- December 2022 Quarterly Activities Report and Appendix 4C
- DARRT-2 Trial Efficacy Phase to Commence
- NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
- September 2022 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
- March 2023 Quarterly Activities Report and Appendix 4C
- Study results show new Sofra drug reduces inflammation
- IONIC Trial Abstract Published at ASCO
- June 2023 Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm